RIPK3是低级别胶质瘤的新型预后标志物并进一步丰富IDH突变状态亚组分层
研究利用公共发现队列(513例)和验证队列(134例)进行Kaplan-Meier生存分析及单因素和多因素Cox回归,评估RIPK3在低级别胶质瘤中的预后价值。结果显示RIPK3是独立预后标志物,高表达与死亡风险增加相关,且RIPK3表达水平可将IDH突变型和野生型患者进一步分为不同风险组。
要点
- RIPK3是低级别胶质瘤患者的独立预后标志物。
- 高RIPK3表达水平与死亡风险增加相关。
- RIPK3表达水平可进一步拆分IDH突变型和野生型患者为不同风险组。
核心结论
- RIPK3表达水平可与IDH突变状态联合用于更好地对低级别胶质瘤患者进行总生存期亚组分层。
研究设计与样本
- 研究使用公共发现队列(513例患者)和验证队列(134例患者),进行Kaplan-Meier生存分析及单因素和多因素Cox回归模型。
主要发现
- RIPK3是低级别胶质瘤患者的独立预后标志物,即使控制年龄和分子或组织学诊断标准后仍独立。
- 高RIPK3表达水平与死亡风险增加相关,这与先前在其他癌症中的报道相反。
- RIPK3表达水平进一步将IDH突变型和野生型患者分别拆分为不同的风险组。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Necroptosis is a necrotic-like cell death pathway in which Receptor-interacting serine/threonine-protein kinase 3 (RIPK3) plays a central role and may induce inflammation and immunity. Lower RIPK3 levels have been correlated with a poor prognosis in breast and colorectal cancer patients. Instead, in gliomas, the most prevalent among central nervous system cancers, necrosis concurs with a more aggressive and lethal outcome, suggesting that, in these cases, necrotic-like pathways may be linked to worse prognoses. Lower-grade gliomas (LGG) exhibit highly diverse clinical behaviors, ranging from slow-paced growth to fast progression to glioblastoma yet patient outcomes cannot be fully predicted through the available markers. To date, IDH mutational status is the most broadly used prognostic marker, albeit several candidates have been proposed to refine LGG subgrouping. Here, we aimed to assess RIPK3 role as a prognostic marker for LGG patients, independently of or in combination with IDH. METHODS: Using publicly available discovery (513 patients) and validation (134 patients) cohorts, we performed Kaplan Meier survival analysis and uni- and multivariate Cox regression models. RESULTS: RIPK3 is an independent prognostic marker in LGG patients, even when controlled by age and molecular or histological diagnostic criteria. Contrary to what was previously reported for other cancers, high RIPK3 expression levels correlates with an increased risk of death. Importantly, RIPK3 expression levels further split both the mutant and wild-type IDH patients into distinct risk groups. CONCLUSION: RIPK3 expression levels can be used in combination with IDH mutational status to better subgroup LGG patients regarding overall survival.
引用
- Vergara GA, Eugenio GC, Malheiros SMF, et al. RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping. J Neurooncol. 2020. PMID: 32222932. doi:10.1007/s11060-020-03473-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。